Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on quercetin and senolytic biology. It is for informational purposes only and is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, supplement regimen, or any health-related decision, particularly if you take prescription medications or manage a chronic health condition.

TL;DR

• Quercetin is a dietary flavonol found at high concentrations in onion outer layers — especially in the yellow and red varieties grown in Japan’s Awaji Island (淡路島) and Hokkaido — and in smaller but measurable amounts in apples, capers, green tea, and broccoli
• A 2000 cohort study by Arai and colleagues (Journal of Nutrition) measured flavonol intake in Japanese women and found that onions accounted for the dominant share of an average dietary quercetin intake of approximately 16 mg/day; the same study reported an inverse correlation between quercetin intake and plasma LDL cholesterol concentration
• The senolytic interest in quercetin originates from a 2015 Aging Cell paper by Zhu, Tchkonia, and colleagues at the Kirkland laboratory (Mayo Clinic): quercetin combined with dasatinib — a prescription BCR-ABL tyrosine kinase inhibitor — produced complementary senolytic activity across multiple senescent cell types that neither compound achieved independently
• Phase II human trials on dasatinib + quercetin (D+Q) in diabetic kidney disease (EBioMedicine 2019) and idiopathic pulmonary fibrosis have reported meaningful reductions in senescent cell biomarkers and, in the IPF population, improvements in physical function endpoints — though in disease-specific contexts under clinical supervision with intermittent high-dose protocols
• Calibration: quercetin as a standalone dietary supplement has not been shown in published human trials to produce senolytic activity in isolation. The senolytic evidence involves quercetin at 1,000 mg/day specifically paired with prescription-only dasatinib. Independent quercetin evidence — primarily modest blood pressure effects in hypertensive populations — represents a different and more limited category than the D+Q senolytic work.

What readers are actually deciding about quercetin

The supplement interest in quercetin typically arrives through two research trails. The first is the Japanese dietary flavonoid literature, where quercetin is the dominant flavonol measured in cohort studies and onions are the primary source. The second — and the path that drives most current supplement purchasing — is the D+Q senolytic protocol, where readers encounter quercetin as the non-prescription half of a combination that produced Phase II results.

These two trails lead to different practical questions. The dietary trail asks whether higher onion and apple consumption correlates with the health markers documented in Japanese cohort data — a question with modest but real epidemiological support at dietary intake levels. The senolytic trail asks whether quercetin supplements replicate what the D+Q protocol achieved in clinical trials — and here the honest answer requires separating the mechanism from what quercetin does and does not contribute on its own.

Both deserve direct answers rather than compressed framing.

Quercetin in the Japanese diet: Awaji Island, dietary intake, and the onion concentration question

Onion (Allium cepa) outer dried skin layers carry some of the highest quercetin concentrations measured in any food — typically in the range of 200–600 mg per 100 g dry weight for red and yellow varieties, with inner flesh layers containing substantially less. Japan’s onion production is concentrated in two regions: Awaji Island (淡路島) in Hyogo Prefecture, which is Japan’s most prominent onion-producing area by historical reputation, and Hokkaido, which supplies the majority of domestic volume. Both regions grow primarily yellow and sweet varieties. Variety-level quercetin content for specific Japanese cultivars is not systematically published in accessible food composition literature, but red and yellow variety onions consistently outperform white varieties in international food composition databases on quercetin content — and Awaji’s sweet yellow onion varieties fall within the higher-concentration range for the category.

The Arai et al. study published in Journal of Nutrition in 2000 is the most cited source for quercetin intake estimates in Japanese populations. Using dietary records and food composition data for Japanese women, the study found average total flavonol intake dominated by quercetin at approximately 16 mg/day, with onions accounting for the largest single source, followed by smaller contributions from apples (ringo), green tea, and broccoli. The study reported an inverse correlation between quercetin intake and plasma LDL cholesterol concentration. That correlation is observational — high-quercetin-food consumers also tend to have higher overall vegetable intake — and the study does not establish quercetin as the causal factor.

The dietary intake context matters for one specific reason: 16 mg/day is roughly 60-fold below the 1,000 mg/day quercetin dose used in D+Q senolytic protocols. The onion consumption angle and the senolytic supplement question are connected through quercetin as a molecule, but they represent different dosing contexts and genuinely separate evidence categories.

How quercetin became part of the senolytic research pipeline

The mechanistic background on cellular senescence — how p16^INK4a and p21^CIP1 mediate permanent cell cycle arrest, and how the senescence-associated secretory phenotype (SASP) drives chronic low-grade inflammation in aging tissues — is covered in the cellular senescence and senolytics research article. What matters for the quercetin discussion is where quercetin enters that framework.

The 2015 Aging Cell paper by Zhu, Tchkonia, Pirtskhalava, and colleagues at the Kirkland laboratory at Mayo Clinic screened compounds for selective cytotoxicity in senescent cells across multiple human and mouse cell types. The central finding: dasatinib and quercetin showed complementary rather than redundant senolytic activity. Dasatinib primarily targeted senescent fat progenitor cells through PDGFR, Src, and BCL-2 family survival pathway inhibition. Quercetin showed senolytic activity across a broader panel including senescent human endothelial cells and some hematopoietic stem cell populations, through inhibition of PI3K/AKT survival signaling and BCL-family anti-apoptotic proteins. In aged mice, the combination reduced senescent cell burden across multiple tissue types and was associated with improved physical function measures — effects that neither compound produced independently at comparable levels.

This mechanistic complementarity matters for interpreting the human trial literature. D+Q was designed as a combination because the two agents target different senescent cell populations through distinct survival pathway dependencies. The quercetin portion is not a simple booster of dasatinib’s mechanism — it expands the range of senescent cell types the combination reaches. A reader who assumes the quercetin component alone accounts for D+Q’s documented senolytic activity is reading the mechanism backwards.

The comparison with fisetin — covered in detail in the fisetin and Japanese strawberries article — is instructive here. The 2017 Mayo Clinic polyphenol screening identified fisetin as the most potent standalone natural senolytic candidate among ten tested compounds, with quercetin also appearing in that comparison panel. Quercetin ranked lower on standalone senolytic selectivity in that screen than fisetin did. The reason quercetin has more published Phase II human data is that its clinical trajectory runs through the D+Q combination protocol rather than as a single-agent supplement intervention.

The D+Q human trial record: what intermittent dosing actually achieved

Phase II D+Q research has used intermittent dosing protocols rather than continuous supplementation — typically dasatinib 100 mg/day and quercetin 1,000 mg/day taken on three consecutive days per dosing cycle, repeated over study periods of three to twenty weeks, under clinical supervision.

The 2019 open-label pilot published in EBioMedicine by Kirkland, Hickson, and colleagues enrolled nine patients with diabetic kidney disease. After three weeks of intermittent D+Q dosing, the study found reductions in skin and adipose tissue senescent cell markers measured by p16^INK4a and p21^CIP1 expression, alongside decreases in plasma SASP-related proteins including IL-6, MMP-9, and MCP-1. A sample size of nine positions this as a target engagement and early tolerability assessment rather than a powered efficacy trial.

A Phase II trial of D+Q in patients with idiopathic pulmonary fibrosis (IPF) — a disease involving substantial fibroblast senescence and SASP-driven fibrosis progression — examined physical function endpoints over a 20-week period. Published findings from this work showed improvements in six-minute walk distance in the D+Q arm relative to placebo, a result that attracted attention as meaningful signal in a disease context where SASP is a well-characterized pathological contributor. These results in an IPF population do not generalize directly to aging in otherwise healthy adults.

Research from LeBrasseur’s group at Mayo Clinic examining D+Q in older adults with physical frailty has reported reductions in plasma IL-6 and MMP-3 following intermittent cycles. Effects on physical performance measures have varied across small pilots; larger powered trials are in enrollment as of mid-2026.

The practical boundary to state clearly: dasatinib is a prescription oncology drug with documented toxicity profiles — including pleural effusion and cytopenias at clinical doses — that require physician supervision. The quercetin component is accessible as a dietary supplement. The senolytic evidence, however, involves the combination. Quercetin alone at supplement doses has not produced equivalent senolytic results in the published human trial record.

Quercetin’s standalone evidence: outside the D+Q protocol

Setting aside the senolytic context, quercetin has its own modest human trial record for cardiovascular markers and inflammatory signaling.

A 2009 crossover RCT by Egert and colleagues (British Journal of Nutrition) enrolled overweight subjects with elevated cardiovascular risk and administered quercetin aglycone at 150 mg/day for six weeks. In the pre-hypertensive subgroup, quercetin was associated with a reduction in systolic blood pressure of approximately 3–7 mmHg versus placebo. The effect was not observed in normotensive participants in the same trial — an important qualification for interpreting the signal.

Pooled analyses of RCT data on quercetin and blood pressure have reported mean systolic reductions in the range of 3–5 mmHg across hypertensive and pre-hypertensive populations. The effect size is modest but consistent across multiple independent trial populations. The calibrated interpretation: quercetin supplementation is associated with supporting blood pressure in individuals who already have elevated readings — not a blanket cardiovascular outcome claim.

Quercetin also inhibits the NLRP3 inflammasome in preclinical models — a multiprotein complex associated with IL-1β and IL-18 release in response to cellular stress signals. Whether this mechanism produces clinically meaningful anti-inflammatory effects at supplement doses in healthy humans has not been established in controlled human trials. It contributes to mechanistic interest in quercetin alongside the senolytic work but represents a distinct and earlier-stage evidence category.

Quercetin supplements: form, dose, and what to compare when buying

The quercetin supplement market ranges from basic quercetin anhydrous capsules at 250–500 mg through bioavailability-enhanced formulations, including quercetin phytosomes (phospholipid-bound forms studied for improved intestinal absorption) and quercetin combined with bromelain, an enzyme that may support absorption and carries separate anti-inflammatory research.

Jarrow Formulas QuerFenol at 500 mg is among the more consistently referenced quercetin options in independent supplement comparisons: search Jarrow Formulas quercetin 500mg on Amazon.

Solaray Quercetin with Bromelain is a widely available combination at 500 mg quercetin per serving: search Solaray quercetin bromelain supplement on Amazon.

NOW Foods Quercetin with Bromelain is a lower-cost option at a comparable dose range, appearing frequently in cost-effectiveness comparisons: search NOW Foods quercetin bromelain capsules on Amazon.

For readers comparing options before committing: search quercetin supplement 500mg capsules on Amazon.

One expectation to set directly: the Phase II D+Q trials administered quercetin at 1,000 mg/day during dosing windows alongside prescription dasatinib, in disease-specific patient populations under clinical supervision. No published human trial has established standalone quercetin supplementation as a senolytic at any dose. Purchasing quercetin to replicate the D+Q protocol without dasatinib and without clinical context involves a meaningful gap between the trial evidence and the self-directed application.

Side effects, interactions, and who should discuss this with a clinician first

Quercetin has a documented safety profile at doses up to 1,000 mg/day for 12 weeks across several clinical trials, with mild gastrointestinal effects being the most commonly reported adverse event at higher doses. The more clinically significant concerns involve drug interactions.

CYP enzyme inhibition: quercetin inhibits cytochrome P450 enzymes CYP3A4 and CYP2C9 in cell culture and ex vivo models. CYP3A4 metabolizes a wide range of commonly prescribed medications — including statins, calcium channel blockers, immunosuppressants, anticoagulants, and several antifungals. Whether quercetin at supplement doses produces clinically relevant CYP inhibition in humans has not been systematically characterized in pharmacokinetic interaction trials, but the mechanistic concern applies to a large share of commonly prescribed drug categories.

P-glycoprotein interaction: quercetin inhibits P-glycoprotein efflux transporters in cell culture, which could affect absorption of co-administered drugs that are P-gp substrates. Cyclosporine and digoxin are examples where P-gp interaction data has clinical relevance; quercetin-specific human pharmacokinetic interaction data for these combinations is limited but the theoretical overlap warrants clinical discussion.

Anticoagulants and antiplatelet drugs: quercetin has shown antiplatelet aggregation inhibition in ex vivo models. Anyone taking warfarin, clopidogrel, or aspirin-based antiplatelet regimens should discuss quercetin supplementation with a prescribing clinician before starting.

Thyroid considerations: some animal model and in vitro evidence suggests quercetin may affect thyroid peroxidase activity at higher doses. Human data is insufficient to quantify this in clinical terms, but individuals with thyroid conditions or taking thyroid medications should mention quercetin to a prescribing clinician.

Pregnancy and lactation: no controlled human safety data exists for supplement-level quercetin intake. Standard precautionary avoidance applies.

Who should discuss with a clinician before starting: anyone taking medications metabolized by CYP3A4 or CYP2C9 — a category that covers many commonly prescribed drugs; anyone on anticoagulant or antiplatelet therapy; anyone with thyroid conditions; anyone pregnant or nursing. These are mechanism-specific rather than vague precautionary statements — the relevant enzyme and transporter interactions are documented at the biochemical level even where human pharmacokinetic data for the specific drug combinations remains limited.

For readers following the senolytic research track that quercetin is part of, the cellular senescence mechanisms article covers the D+Q evidence base in the context of the broader senolytic pipeline. The fisetin article covers the natural polyphenol with the strongest standalone senolytic preclinical profile from the same Mayo Clinic screening work. Quercetin’s place in that landscape is specific: it is one half of the most clinically studied natural-synthetic senolytic combination, not a standalone senolytic with equivalent evidence. That distinction matters more for supplement purchasing decisions than the dietary onion connection does.

---

Sources: Arai Y et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr. 2000;130(9):2243–50. | Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–58. | Kirkland JL, Tchkonia T, Lebrasseur NK, et al. Pilot study of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;40:554–63. | Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype. Br J Nutr. 2009;102(7):1065–74. | Serban C, Sahebkar A, Ursoniu S, et al. Effect of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5(7):e002713.